281 related articles for article (PubMed ID: 23496210)
1. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.
Larsen DM; Haberichter SL; Gill JC; Shapiro AD; Flood VH
Haemophilia; 2013 Jul; 19(4):590-4. PubMed ID: 23496210
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
4. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
8. The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13.
Ma Z; Su J; Zhang J; Ling J; Yin J; Bai X; Ruan C
Thromb Res; 2015 Nov; 136(5):987-95. PubMed ID: 26345337
[TBL] [Abstract][Full Text] [Related]
9. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
[TBL] [Abstract][Full Text] [Related]
10. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion.
McKinnon TA; Nowak AA; Cutler J; Riddell AF; Laffan MA; Millar CM
J Thromb Haemost; 2012 Jul; 10(7):1409-16. PubMed ID: 22537243
[TBL] [Abstract][Full Text] [Related]
12. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
[TBL] [Abstract][Full Text] [Related]
13. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
[TBL] [Abstract][Full Text] [Related]
15. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
16. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
Casonato A; Cattini MG; Soldera C; Marcato S; Sartorello F; Pontara E; Pagnan A
J Lab Clin Med; 2004 Nov; 144(5):254-9. PubMed ID: 15570243
[TBL] [Abstract][Full Text] [Related]
17. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
[TBL] [Abstract][Full Text] [Related]
19. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
